As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.

The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.

For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit (angela.steinbach@uk-koeln.de or vassiliki.dimitriou@uk-koeln.de).

Kidney in COVID-19

AcronymISRCTNEudraCTNCT (clinicaltrials.gov)DRKS

Kidney in Coronavirus Disease 2019 Registry

Status: Active

Purpose / Objectives

Primary Outcome

  • Determination of the global incidence of SARS-CoV-2 infections and the resulting effects on kidney function as well as monitoring of global and local developments over time. Determination of outbreak situations

Secondary Outcomes

  •  Determination of the incidence of acute kidney damage in the context of SARS-CoV2 infections
  • Identification of risk groups and risk factors by examining SARS-CoV-2 infections in patients with chronic kidney disease and kidney transplantation
  • Documentation of mortality rates, resources used and additional costs due to SARS-CoV-2 infections to monitor trends both globally and locally over time
  • To assess increasing costs associated with SARS-CoV-2-infections
  • To analyze the effect of SARS-CoV-2-infections on the kidney
  • To analyze the course of disease

 

Diagnosis

Patient attributes

Inclusion criteria

  • Virology evidence of SARS-CoV-2-infection
  • Pathological evidence of SARS-CoV-2-infection

Exclusion criteria

  • Occurrence of ARDS (acute respiratory distress syndrome) without evidence of SARS-CoV-2 infection
  • Acute kidney injury without evidence of SARS-CoV-2 infection

Trial design

  • Phase IV
  • Multicenter
  • Retrospective
  • Two-arm

Intervention

No intervention.

Documents (password protected)

Responsibilities in overall trial

National Coordinating Investigator

PD Dr. med. Volker Burst

Data management

Studienzentrum Med II